-
2024-516443-57-00
4
2023-10-11
Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh B, ALBI gr
-
2023-506081-31-00
5
2022-03-29
Traumatic Injury
-
2024-513983-24-00
6
2021-10-29
Diabetic Macular Oedema
-
2024-514843-27-00
6
2021-10-11
Severe asthma
-
2024-517215-67-00
5
2021-06-11
Newly diagnosed Non-Frail transplant Ineligible Multiple Myeloma elder
-
2023-505737-26-00
5
2020-07-22
Steroid refractory Acute Graft versus host Disease
-
2022-501050-11-01
10
2020-07-13
Acute Lymphoblastic Leukaemia
-
2024-511862-35-00
4
2019-07-19
Adults with non-contrast-enhancing diffuse brainstem gliomas with non-
-
2024-514780-26-00
4
2018-10-23
Patients ≤50 years old with high-risk osteosarcoma (defined as metasta
-
2023-506027-29-00
5
2014-10-01
Children, adolescents and adults with newly diagnosed diffuse intrinsi
-
2024-519025-37-00
1
2025-06-19
Dry age-related macular degeneration.
-
2024-518669-83-00
4
2024-12-05
acute promyelocytic leukemia (APL) in children and adolescents
-
2023-508235-31-00
5
2024-06-17
Atopic Dermatitis
-
2024-516914-39-00
5
2022-04-27
Metastatic or unresectable melanoma
-
2023-510450-16-00
1
2020-12-16
Phase 1: Advanced solid tumors harboring genetic alterations in MET
-
2024-515331-30-00
7
2020-10-30
Primary Central Nervous System Lymphoma (PCNSL)
-
2024-511653-22-00
5
2020-02-12
Cutaneous Squamous Cell Carcinoma (CSCC)
-
2023-504303-86-00
5
2019-11-21
High-risk hepatocellular carcinoma (HCC)
-
2024-516847-23-00
4
2019-08-27
ER-positive and HER2-negative metastatic or locally advanced breast ca
-
2024-514705-62-00
5
2019-07-08
Recurrent rectal cancer after local excision
-
2024-514309-73-00
5
2018-02-06
Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation
-
2024-516112-21-00
5
2017-11-20
Newly diagnosed acute myeloid leukaemia (AML), high risk myelodysplast
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia
-
2024-512160-58-00
6
2025-02-12
Cerebral palsy with pathological drooling